DaVita (NYSE:DVA – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $2.14 per share and revenue of $3.27 billion for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
DaVita Price Performance
NYSE DVA opened at $173.45 on Monday. DaVita has a 12-month low of $108.76 and a 12-month high of $179.60. The firm’s 50 day moving average is $160.59 and its 200-day moving average is $156.53. The company has a market capitalization of $14.22 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.
Analysts Set New Price Targets
Separately, Barclays lifted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $161.80.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- How to Calculate Inflation Rate
- 3 Volatility ETFs to Help You Profit from Market Chaos
- Investing In Preferred Stock vs. Common Stock
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.